Woodline Partners LP Atai Life Sciences N.V. Transaction History

Woodline Partners LP

  • $11 Billion
  • Q3 2024

A detailed history of Woodline Partners LP transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Woodline Partners LP holds 535,047 shares of ATAI stock, worth $636,705. This represents 0.01% of its overall portfolio holdings.

Number of Shares
535,047
Holding current value
$636,705
% of portfolio
0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.16 - $1.64 $620,654 - $877,477
535,047 New
535,047 $620,000
Q1 2023

May 15, 2023
BUY
$1.17 - $2.7 $277,810 - $641,101
237,445 Added 119.12%
436,776 $790,000
Q4 2022

Feb 14, 2023
SELL
$2.38 - $3.55 $1.73 Million - $2.58 Million
-725,916 Reduced 78.46%
199,331 $530,000
Q3 2022

Nov 14, 2022
BUY
$3.14 - $4.87 $550,156 - $853,267
175,209 Added 23.36%
925,247 $3.06 Million
Q2 2022

Aug 15, 2022
SELL
$3.03 - $5.32 $41,989 - $73,724
-13,858 Reduced 1.81%
750,038 $2.73 Million
Q1 2022

May 16, 2022
SELL
$4.66 - $7.66 $345,445 - $567,835
-74,130 Reduced 8.85%
763,896 $3.89 Million
Q4 2021

Feb 14, 2022
BUY
$6.82 - $17.8 $600,207 - $1.57 Million
88,007 Added 11.73%
838,026 $6.39 Million
Q3 2021

Nov 15, 2021
SELL
$13.62 - $19.48 $566,128 - $809,705
-41,566 Reduced 5.25%
750,019 $11.1 Million
Q2 2021

Aug 16, 2021
BUY
$16.94 - $19.89 $13.4 Million - $15.7 Million
791,585 New
791,585 $14.6 Million

Others Institutions Holding ATAI

# of Institutions
87
Shares Held
12.4M
Call Options Held
77.8K
Put Options Held
50.3K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $197M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email